Cargando…
Correction to: 571. A Report of the Postmarketing Spontaneous Safety Data over 24 Years for GSK’s Measles-Mumps-Rubella (MMR) Vaccine
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166515/ https://www.ncbi.nlm.nih.gov/pubmed/37168799 http://dx.doi.org/10.1093/ofid/ofad249 |
Ejemplares similares
-
571. A Report of the Postmarketing Spontaneous Safety Data over 24 Years for GSK’s Measles-Mumps-Rubella (MMR) Vaccine
por: Singh, Tina, et al.
Publicado: (2022) -
Clinical trials show similar safety outcomes including febrile convulsion rates for GSK’s and Merck’s measles-mumps-rubella (MMR) vaccines
por: Habib, Md Ahsan, et al.
Publicado: (2023) -
Response to Measles, Mumps and Rubella (MMR) Vaccine in Transfusion-Dependent Patients
por: Casale, Maddalena, et al.
Publicado: (2021) -
Analysis of Measles-Mumps-Rubella (MMR) Titers of Recovered COVID-19 Patients
por: Gold, Jeffrey E., et al.
Publicado: (2020) -
Are Measles-Mumps-Rubella (MMR) Antibodies Friends or Foes for Covid-19 Disease?
por: Salamony, Azza, et al.
Publicado: (2023)